Pathogenesis of Hematologic Malignancies
Launched by OHSU KNIGHT CANCER INSTITUTE · Nov 13, 2012
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Suspected or confirmed diagnosis of AL, LPD, MDS, or MPD
- • Male or female of all ages
- • Willing and able to sign informed consent
- • Willing guardian consent for participants under 18 years of age
- Exclusion Criteria:
- • No suspected or confirmed diagnosis of acute leukemias (AL), lymphoproliferative disorders (LPD), myelodysplastic syndromes (MDS), or myeloproliferative diseases (MPD)
About Ohsu Knight Cancer Institute
The OHSU Knight Cancer Institute is a leading research and treatment center dedicated to advancing cancer care through innovative clinical trials and groundbreaking research. Part of Oregon Health & Science University, the institute is recognized for its multidisciplinary approach, combining expertise in oncology, genomics, and patient care to develop novel therapies and improve treatment outcomes. With a commitment to translating scientific discoveries into clinical applications, the OHSU Knight Cancer Institute strives to enhance the quality of life for cancer patients while fostering collaboration among researchers, clinicians, and the community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Portland, Oregon, United States
Patients applied
Trial Officials
Marc Loriaux, MD
Principal Investigator
OHSU Knight Cancer Institute
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials